To include your compound in the COVID-19 Resource Center, submit it here.

Gilead, Cubist terminate Cidecin deal

The companies mutually terminated their 2001 deal, in which GILD received exclusive European commercialization rights to CBST's Cidecin

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE